Annovis Bio Inc. (NYSE: ANVS) has achieved a notable milestone with the issuance of a U.S. patent for its leading drug candidate, buntanetap, which is being investigated for the treatment of acute traumatic brain injuries (TBI). This patent, U.S. Patent No. 12,042,482, covers methods for utilizing buntanetap to treat TBI and prevent nerve cell death.

The patent application, initially filed in 2016, included various nerve injury treatments such as TBI, stroke, and spinal cord injuries. While these claims were approved in Europe and other regions, the U.S. Patent and Trademark Office required them to be separated into individual patents. The recent grant of this patent strengthens Annovis Bio’s intellectual property portfolio.

Annovis, expressed her enthusiasm about this achievement. “Securing this patent for buntanetap is a significant milestone,” she said. “Nerve cell death is a common issue in numerous brain disorders, not just Alzheimer’s and Parkinson’s. Our preclinical studies in animal models of TBI and stroke have demonstrated buntanetap’s ability to prevent cell death and maintain function, which is crucial for addressing brain trauma—a significant concern in the U.S.”

This new patent addition to Annovis Bio’s portfolio, which already includes patents for buntanetap in various neurodegenerative and mental health disorders, highlights the company's commitment to innovative approaches aimed at restoring brain function and enhancing patient outcomes.

Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by blocking the formation of neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This mechanism helps improve synaptic transmission, support axonal transport, and reduce neuroinflammation. By addressing these pathways, buntanetap has the potential to reverse neurodegeneration in conditions such as Alzheimer’s and Parkinson’s, aiming to restore brain function and improve patients' quality of life.

 

Source: globenewswire.com

Report Abuse